Periodic paralysis

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:206976G72.3
Who is this for?
Show terms as
7Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Periodic paralysis is a group of rare neuromuscular disorders characterized by episodes of muscle weakness or paralysis that occur intermittently, with normal or near-normal muscle function between attacks. The condition primarily affects skeletal muscles and is caused by dysfunction of ion channels (channelopathies) in muscle cell membranes, most commonly involving sodium, calcium, or potassium channels. The major subtypes include hypokalemic periodic paralysis (HypoPP), hyperkalemic periodic paralysis (HyperPP), and Andersen-Tawil syndrome. Attacks can be triggered by factors such as carbohydrate-rich meals, rest after exercise, stress, cold exposure, or changes in serum potassium levels. During episodes, patients experience flaccid weakness that can range from mild focal weakness to severe generalized paralysis, typically sparing respiratory and cardiac muscles. Episodes may last from minutes to hours or even days depending on the subtype. Between attacks, patients may initially have normal strength, but over time many individuals develop a progressive fixed myopathy (permanent muscle weakness) that can significantly impact mobility and quality of life. In Andersen-Tawil syndrome, cardiac arrhythmias and distinctive facial and skeletal features may also be present. Diagnosis is based on clinical history, electromyography (including the long exercise test), genetic testing, and provocative testing in specialized centers. Treatment focuses on preventing attacks and managing acute episodes. Carbonic anhydrase inhibitors such as acetazolamide and dichlorphenamide are commonly used as preventive therapies. Potassium supplementation is used in hypokalemic forms, while dietary modifications and avoidance of known triggers are important management strategies. Dichlorphenamide (Keveyis) is the only FDA-approved medication specifically indicated for primary periodic paralysis. Long-term monitoring for progressive myopathy and, in Andersen-Tawil syndrome, cardiac surveillance are essential components of care.

Inheritance

Autosomal dominant

Passed on from just one parent; each child has about a 50% chance of inheriting it

Age of Onset

Childhood to adulthood

Can begin any time from childhood through adulthood

Orphanet ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Periodic paralysis.

View clinical trials →

No actively recruiting trials found for Periodic paralysis at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Periodic paralysis community →

Specialists

7 foundView all specialists →
WM
Wallaya Jongjaroenprasert, MD
Specialist
PI on 1 active trial1 Periodic paralysis publication
JP
Jill Heathcock, MPT, PhD
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Periodic paralysis.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Periodic paralysisForum →

No community posts yet. Be the first to share your experience with Periodic paralysis.

Start the conversation →

Latest news about Periodic paralysis

No recent news articles for Periodic paralysis.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Periodic paralysis

What is Periodic paralysis?

Periodic paralysis is a group of rare neuromuscular disorders characterized by episodes of muscle weakness or paralysis that occur intermittently, with normal or near-normal muscle function between attacks. The condition primarily affects skeletal muscles and is caused by dysfunction of ion channels (channelopathies) in muscle cell membranes, most commonly involving sodium, calcium, or potassium channels. The major subtypes include hypokalemic periodic paralysis (HypoPP), hyperkalemic periodic paralysis (HyperPP), and Andersen-Tawil syndrome. Attacks can be triggered by factors such as carbohy

How is Periodic paralysis inherited?

Periodic paralysis follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Periodic paralysis typically begin?

Typical onset of Periodic paralysis is childhood to adulthood. Age of onset can vary across affected individuals.

Which specialists treat Periodic paralysis?

7 specialists and care centers treating Periodic paralysis are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.